Exelixis Inc (EXEL)

Price $64.53 · -1.19% today · $16B market cap.

biotech_pharma

Strongest Overalllow risk← Back

Simulated history. Equities don't yet have ingested OHLCV, so the price chart and technical indicators below are illustrative (deterministic, labelled) — not real market history.

Price & Performance

$64.53 +4.1% over 1Y

Simulated history — illustrative, not real market data.

Today

-1.19%

1 week

+2.95%

1 month

+10.48%

1 year

+69.59%

Technical Analysis

RSI (14)

65.30

MACD

0.78

MACD signal

-0.28

MACD hist

1.05

SMA 20

57.52

SMA 50

59.90

EMA 20

58.75

ATR (14)

2.15

Support

52.57

Resistance

64.71

Bollinger upper

62.82

Bollinger lower

52.23

▹ RSI 65 — neutral
▹ MACD above signal (bullish)
▹ Price above 20/50-day averages

Indicators describe past price action — they do not predict future direction.

Fundamental Analysis

P/E ratio

18.58

Return on equity

42.49%

EBITDA

n/a

EPS (TTM)

3.18

Net debt

n/a

Net margin

35.33%

Gross margin

96.48%

Current ratio

3.46

Debt / Equity

0.00

Dividend yield

n/a

Operating margin

39.88%

Revenue growth (YoY)

9.23%

Risk Assessment

Ann. volatility

48.1%

Max drawdown

34.2%

Liquidity

Adequate market capitalization

Leverage

Debt/equity 0.0 (manageable)

Valuation

P/E 19×

Earnings

Earnings dates are not tracked in this release.

Concentration

Single-name equity — no diversification within the position.

Estimated annualized volatility 48% with a maximum drawdown of 34% over the available window.

Investment Thesis (generated summary)

Exelixis Inc (EXEL) screens constructively on the current data, with an opportunity score of 71/100. The score reflects the available fundamental, technical, valuation and sentiment inputs — it is a research screen, not a forecast or a recommendation to trade.

Bullish case

Strong net margin (35%)
Revenue growth modest (9% y/y)
Reasonable P/E (19×)
Outperforming peers over the past month

Potential catalysts

Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy
BeOne Stock Tests Buy Zone With Visions Of 177% Earnings Growth. Watch This Clue.
Exelixis Rises with Earnings on Tap

Horizon: ~1–3 months for technical signals; 12+ months for fundamental quality.

Thesis invalidated if: Momentum reverses and price breaks below its 50-day average; Earnings or guidance disappoint relative to consensus; A sector-level drawdown outweighs stock-specific strength.

News Sentiment

Bullish 50%Neutral 37.5%Bearish 12.5%